http://orcid.org/0000-0003-3418-3362
Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Angela Genge & Adriano Chio. (2023) The future of ALS diagnosis and staging: where do we go from here?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 24:3-4, pages 165-174.
Read now
Read now
Ruben P.A. van Eijk, Adriaan D. de Jongh, Stavros Nikolakopoulos, Christopher J. McDermott, Marinus J.C. Eijkemans, Kit C.B. Roes & Leonard H. van den Berg. (2021) An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 22:3-4, pages 300-307.
Read now
Read now
R Hergesheimer, D Lanznaster, P Vourc’h, Cr Andres, Se Bakkouche, S Beltran, H Blasco, P Corcia & P Couratier. (2020) Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy 21:9, pages 1103-1110.
Read now
Read now
Nimish J. Thakore, Brittany R. Lapin & Erik P. Pioro. (2020) Stage-specific riluzole effect in amyotrophic lateral sclerosis: a retrospective study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 21:1-2, pages 140-143.
Read now
Read now
. (2019) Theme 1 Epidemiology and informatics. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:sup1, pages 101-113.
Read now
Read now
Carlayne Jackson, Terry Heiman-Patterson, Pamela Kittrell, Tatyana Baranovsky, Glenn McAnanama, Laura Bower, Wendy Agnese & Mike Martin. (2019) Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:7-8, pages 605-610.
Read now
Read now
Articles from other publishers (14)
Juliette Ortholand, Pierre-François Pradat, Sophie Tezenas du Montcel & Stanley Durrleman. (2023) Interaction of sex and onset site on the disease trajectory of amyotrophic lateral sclerosis. Journal of Neurology 270:12, pages 5903-5912.
Crossref
Crossref
Veria Vacchiano, Andrea Mastrangelo, Corrado Zenesini, Simone Baiardi, Patrizia Avoni, Barbara Polischi, Sabina Capellari, Fabrizio Salvi, Rocco Liguori & Piero Parchi. (2023) Elevated plasma p-tau181 levels unrelated to Alzheimer’s disease pathology in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 94:6, pages 428-435.
Crossref
Crossref
Umberto Manera, Fabrizio D'Ovidio, Sara Cabras, Maria Claudia Torrieri, Antonio Canosa, Rosario Vasta, Francesca Palumbo, Maurizio Grassano, Fabiola De Marchi, Letizia Mazzini, Gabriele Mora, Cristina Moglia, Andrea Calvo & Adriano Chiò. (2023) Amyotrophic lateral sclerosis regional progression intervals change according to time of involvement of different body regions. European Journal of Neurology 30:4, pages 872-880.
Crossref
Crossref
Erica Tavazzi, Roberto Gatta, Mauro Vallati, Stefano Cotti Piccinelli, Massimiliano Filosto, Alessandro Padovani, Maurizio Castellano & Barbara Di Camillo. (2023) Leveraging process mining for modeling progression trajectories in amyotrophic lateral sclerosis. BMC Medical Informatics and Decision Making 22:S6.
Crossref
Crossref
Brittany Lapin, Kedar Mate, Yadi Li & Nimish Thakore. (2022) Subjective health perception prioritizes psychological well-being over physical function in advanced ALS: A multigroup structural equation modeling analysis. Journal of the Neurological Sciences 442, pages 120442.
Crossref
Crossref
Ruben P A van Eijk, L H van den Berg & Ying Lu. (2022) Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF). Journal of Neurology, Neurosurgery & Psychiatry 93:5, pages 539-546.
Crossref
Crossref
Alessandro Introna, Giammarco Milella, Antonella Morea, Maria Ucci, Angela Fraddosio, Stefano Zoccolella, Eustachio D'Errico & Isabella Laura Simone. (2021) King's college progression rate at first clinical evaluation: A new measure of disease progression in amyotrophic lateral sclerosis. Journal of the Neurological Sciences 431, pages 120041.
Crossref
Crossref
Lu Xu, Bingjie He, Yunjing Zhang, Lu Chen, Dongsheng Fan, Siyan Zhan & Shengfeng Wang. (2021) Prognostic models for amyotrophic lateral sclerosis: a systematic review. Journal of Neurology 268:9, pages 3361-3370.
Crossref
Crossref
Vincent Grollemund, Gaétan Le Chat, Marie-Sonia Secchi-Buhour, François Delbot, Jean-François Pradat-Peyre, Peter Bede & Pierre-François Pradat. (2020) Manifold learning for amyotrophic lateral sclerosis functional loss assessment. Journal of Neurology 268:3, pages 825-850.
Crossref
Crossref
Nimish J. Thakore, Erik P. Pioro, Belinda L. Udeh, Brittany R. Lapin & Irene L. Katzan. (2020) A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole. Value in Health 23:12, pages 1543-1551.
Crossref
Crossref
Monika Barczewska, Stanisław Maksymowicz, Izabela Zdolińska-Malinowska, Tomasz Siwek & Mariusz Grudniak. (2020) Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis: an Original Study. Stem Cell Reviews and Reports 16:5, pages 922-932.
Crossref
Crossref
Rangariroyashe Hannah Chipika, Eoin Finegan, Stacey Li Hi Shing, Orla Hardiman & Peter Bede. (2019) Tracking a Fast-Moving Disease: Longitudinal Markers, Monitoring, and Clinical Trial Endpoints in ALS. Frontiers in Neurology 10.
Crossref
Crossref
Vincent Grollemund, Pierre-François Pradat, Giorgia Querin, François Delbot, Gaétan Le Chat, Jean-François Pradat-Peyre & Peter Bede. (2019) Machine Learning in Amyotrophic Lateral Sclerosis: Achievements, Pitfalls, and Future Directions. Frontiers in Neuroscience 13.
Crossref
Crossref
Yana Yunusova, Emily K. Plowman, Jordan R. Green, Carolina Barnett & Peter Bede. (2019) Clinical Measures of Bulbar Dysfunction in ALS. Frontiers in Neurology 10.
Crossref
Crossref